Bevacizumab (Bev) in combination with XELOX or FOLFOX-4: updated efficacy results from XELOX-1 / NO16966, a randomized phase III trial in first-line metastatic.
XELOX-1/NO16966, a randomized phase III trial of first-line XELOX vs. FOLFOX-4 for patients with metastatic colorectal cancer (MCRC): Updated overall survival.
BOPA 2009 Clinical Update: Colorectal Cancer Dr Nick Maisey.
XELOX vs. FOLFOX4: survival and response results from XELOX-1 / NO16966, a randomized phase III trial of first-line treatment for patients with metastatic.
BOPA 2009
A Report from ASCO 2007 First-Line Metastatic Colorectal Cancer
